Published in final edited form as:

J Org Chem. 2020 October 02; 85(19): 12012–12023. doi:10.1021/acs.joc.0c01863.

Pathway engineering of anthracyclines: Blazing trails in natural product glycodiversification

Katelyn V. Brown¹, Benjamin Nji Wandí², Prof. Mikko Metsä-Ketelä, Ph.D.², Prof. S. Eric Nybo, Ph.D.^{1,*}

¹Department of Pharmaceutical Sciences, Ferris State University, College of Pharmacy, Big Rapids, MI 49307, United States of America. ²Department of Biochemistry, University of Turku, FIN-20014, Turku, Finland.

Abstract

The anthracyclines are structurally diverse anticancer natural products that bind to DNA and poison the topoisomerase II – DNA complex in cancer cells. Rational modifications in the deoxysugar functionality are especially advantageous for synthesizing drugs with improved potency. Combinatorial biosynthesis of glycosyltransferases and deoxysugar synthesis enzymes is indispensable for the generation of glycodiversified anthracyclines. This Synopsis considers recent advances in glycosyltransferase structural biology and site-directed mutagenesis, pathway engineering, and deoxysugar combinatorial biosynthesis with a focus on the generation of “new-to-nature” anthracycline analogs.

Graphical Abstract

The actinomycetes are an order of gram-positive bacteria that occupy a wide range of terrestrial and marine habitats¹. Actinomycetes produce a plethora of bioactive substances notable for their antibacterial, anticancer, and immunosuppressive activities². Among these bioactive substances, the anthracyclines are some of the most structurally diverse and important chemicals for their potent anticancer and antibacterial properties³. The

*Corresponding Author – S. Eric Nybo, Department of Pharmaceutical Sciences, College of Pharmacy, Ferris State University, Big Rapids, Michigan 49307, United States of America; EricNybo@Ferris.edu.

anthracyclines exhibit a characteristic anticancer mechanism of action involving intercalation into DNA and poisoning of topoisomerase II-mediated unwinding of DNA supercoils⁴. The anthraquinone moiety of the anthracyclines intercalates between DNA bases, while the carbohydrate unit at 7-position enhances binding through interactions with the minor groove of DNA (Figure 1A). Anthracyclines can undergo redox activation by chelating cellular Fe²⁺, which can lead to the formation of hydroxyl free radicals that cause additional macromolecular damage to DNA and RNA⁵. The aminosugar moiety can form methylene adducts with guanine in the minor groove of DNA (Figure 1B)⁶. The aminosugar also enhances water solubility, plays a role in substrate recognition by *p*-glycoprotein (i.e. mutations in *p*-glycoprotein are responsible for cellular resistance), and impacts clearance of the drug from the body^{7–9}. The anthracyclines suffer from dose-limiting cardiotoxicity¹⁰, which has motivated efforts to study the biosynthesis of the anthracyclines and to generate new drug analogs with improved clinical properties. The combination of DNA and chromatin damage has been shown to be the main cause of cardiotoxicity of doxorubicin¹¹. The modification of doxorubicin to *N,N*-dimethyl-doxorubicin abrogated double-stranded break activity, while retaining the ability to induce chromatin damage. Mouse models showed no cardiotoxicity after treatment with *N,N*-dimethyl doxorubicin¹¹. This suggests that the development of next-generation clinical anthracyclines might be achieved through modification of the carbohydrate units.

The anthracyclines are aromatic polyketides with a 7,8,9,10-tetrahydro-tetracene-5,12-quinone scaffold and between one to eight saccharide moieties attached^{12,13}. At least 500 naturally occurring anthracyclines have been isolated to date¹⁴. The polyketide scaffold exhibits great structural diversity in nature, however, only six of the fifteen possible types of *peri*-hydroxyanthraquinone chromophores have been described to date. In addition, anthracyclines feature *O*-glycosides primarily at phenolic oxygens at 7-position and/or 10-position, although in a few cases *O*-glycosylation is observed at 1-position and 4-position¹⁴. Examples of well-characterized anthracyclines include daunorubicin (**1**), doxorubicin (**2**), nogalamycin (**3**), aclacinomycin (**4**), elloramycin (**5**), 8-demethyl-tetracenomycin C (8-DMTC, **6**), and keyicin (**7**) (Figure 2).

Anthracyclines undergo similar biosynthetic routes via a type II polyketide synthase (PKS), though their structural diversity derives in large part from the complement of post-PKS tailoring enzymes¹⁵. The biosynthesis of doxorubicin involves the iterative condensation of an acetyl-CoA or propionyl-CoA starter unit (e.g. synthesized and transferred by acyltransferase DpsC and propionyl-CoA synthetase DpsD) with nine malonyl-CoA extender units by a minimal PKS composed of ketoacyl synthase alpha (KS α , DpsA), ketoacyl synthase beta (KS β , DpsB), acyl carrier protein (ACP, DpsG) (Figure 3)^{16,17}. The minimal PKS forms an extended complex with a 9-ketoreductase (DpsE), aromatase (DpsF), and second/third-ring cyclase (DpsY) before undergoing C-12 anthraquinol oxygenation (DnrG) and release of the first isolable tricyclic intermediate, aklanonic acid, that is common to most anthracycline biosynthetic pathways¹⁸. Additional *O*-methylation (DnrC), fourth ring cyclization (DnrD), and 7-ketoreduction (DnrE) yields aklavinone (**8**)¹⁹. C-11 oxygenation gives rise to the aglycone *e*-rhodomycinone (**9**)²⁰. TDP-I-daunosamine (**10**) and TDP-I-rhodosamine (**11**) are the most common aminosugars appended to the 7-position for

most of the anthracyclines¹⁴. The biosynthesis of **10** starts from d-glucose-6-phosphate, which is interconverted to d-glucose-1-phosphate by phosphoglucomutase (Pgm) (Figure 3). TDP-glucose-synthase (GS, DnmL/RfbA) condenses thymidine monophosphate with d-glucose-1-phosphate to form TDP-d-glucose, which is then 6-deoxygenated by NDP-d-glucose-4,6-dehydratase (4,6-DH, DnmM/RfbB) to form TDP-4-keto-6-deoxy-d-glucose²¹. TDP-4-keto-6-deoxy-d-glucose then undergoes 2-deoxygenation via 2,3-dehydratase (2,3-DH, DnmT), 3-aminotransfer (AT, DnmJ), 3,5-epimerization (EPI, DnmU), and 4-ketoreduction (4-KR, DnmV) to afford **10** (Figure 3)^{22–25}. **10** undergoes dual *N*-methylations to form **11**.

Glycosylation at the 7-position of aglycone **9** to form rhodomycin D (**12**) requires the action of two enzymes to function properly, one *O*-glycosyltransferase (e.g. DnrS) and a P450-auxiliary protein (e.g. DnrQ) that is hypothesized to function as an allosteric activator^{26,27}. Inactivation of either DnrQ or DnrS in the daunorubicin producer *Streptomyces peucetius* resulted in the accumulation of the aglycone **9**, demonstrating the essentiality of both gene products for glycosylation of **12**. The structure of the erythromycin desosaminyltransferase EryCIII in complex with its activating P450 homolog, EryCII, demonstrated that these enzymes form an $\alpha 2\beta 2$ heterodimer²⁸. EryCII forms tight non-covalent interactions with EryCIII that putatively causes a conformational shift in the *N*-terminus aglycone acceptor and *C*-terminus sugar donor domains that results in the transfer of TDP-d-desosamine to 3- α -mycarosylerythronolide B²⁸. The co-expression of the P450 homolog DesVIII along with desosaminyltransferase DesVII enhances glycosylation efficiency by 10³-fold as compared to DesVII alone²⁹. The glycosyltransferases of anthracycline pathways (e.g. DnrQS, AknST) are thought to function similarly and could be worthy targets for future structural biology studies.

Compound **12** undergoes additional methyl esterase (DnrP) and 4-*O*-methyltransferase (DnrK) activity to afford 13-deoxy-daunorubicin (**13**)³⁰. **13** is oxygenated at 13-position by CYP450 oxygenase DoxA to form **1** and is then hydroxylated at 14-position to afford **2**³¹. The characterization of the doxorubicin biosynthetic pathway provides a fertile substratum for metabolic engineering of the pathway to improve production titers and to generate new anthracyclines via combinatorial biosynthesis. In this Synopsis, we first consider recent advances in pathway engineering of deoxysugar metabolism and polyketide biosynthesis, including substrate precursor engineering and overexpression of rate-limiting structural genes (Figure 4). Pathway engineering is a powerful technique for redirecting carbon flux from primary cellular metabolism towards the production of anthracyclines. Secondly, we discuss the recent discovery of the **7** biosynthetic pathway, which employed state-of-the-art techniques, such as deep transcriptomic sequencing and co-culturing to elicit expression of a cryptic pathway. Thirdly, we describe initial endeavors to elucidate the structural biology of anthracycline glycosyltransferase SnogD and the rational site-directed mutagenesis of substrate-flexible ElmGT. Fourthly, we examine recent efforts to exchange the appended deoxysugar moiety with non-natural deoxysugar donors via the combinatorial biosynthesis of deoxysugar biosynthesis genes. These recent advances have expanded the toolbox for combinatorial biosynthesis of these impressive biosynthetic pathways, which could usher in the next generation of anthracyclines with improved biological activities.

1. Pathway Engineering

1.1. Overexpression of structural biosynthetic genes

Streptomyces peucetius exhibits notable limitations concerning doxorubicin production that have engendered pathway engineering efforts to overcome rate-limiting blocks in the production³². Some of these limitations include poor glycosylation efficiency, low expression of deoxysugar biosynthetic genes, low conversion of **1** to **2** by DoxA, and feedback regulation^{24–26,31}. Consequently, pathway engineering provides an attractive solution for overcoming transcriptional imbalances via overexpression of structural biosynthetic genes. The overexpression of the glycosyltransferase DnrS alone or together with the DnrQ auxiliary protein resulted in a 1.2 or 2.8-fold, respectively, increase in **2** production titers³³. The overexpression of the deoxysugar biosynthesis enzymes TDP-d-glucose synthase (e.g. DesIII) and TDP-d-glucose-4,6-dehydratase (e.g. DesIV) increased production by 2.6-fold. The combined overexpression of *desIII/desIV* and *dnrQ/dnrS* demonstrated a synergistic 5.6-fold increase in **2** production titers.

1.2. Substrate precursor engineering

Overexpression of structural biosynthetic genes is one successful approach towards improving anthracycline production titers, but substrate precursor engineering of biochemical building blocks (e.g. acetyl-CoA, d-glucose-6-phosphate) is a promising technique to funnel carbon from central metabolism towards polyketide biosynthesis. Overexpression of phosphoglucomutase (Pgm, *sco7443*) and the acetyl-CoA carboxylase complex (ACCase, *ovmGIH*) increased precursor substrate levels of glucose-1-phosphate and malonyl-CoA, respectively, which ubiquitously enhanced production titers of **2**, **3**, **5**, **6**, and steffimycin by 20–60% (Figure 4)³⁴. The same technique has also been utilized in *Streptomyces argillaceus* to increase the production of the anticancer polyketide, mithramycin by overexpressing Pgm and ACCase³⁵. Overexpression of *sco7443* resulted in higher titers of mithramycin early in the logarithmic growth phase of the engineered strain (e.g. 180% after 3 days and 62% after 4 days) before leveling off to a 9% increase as compared to *S. argillaceus* harboring an empty plasmid vector. This result was further supported by a decrease in d-glucose-6-phosphate concentrations (e.g. 6% - 61%) and an increase in d-glucose-1-phosphate concentrations (e.g. 15% to 34%) in the engineered strain. Overexpression of *ovmGIH* increased malonyl-CoA titers in the engineered strain by 3-fold as compared to wildtype *S. argillaceus*. Also, overexpression of *ovmGIH* in *S. argillaceus* resulted in an increase in mithramycin production by 21%. Most importantly, overexpression of both *ovmGIH* and *sco7443* in the *S. argillaceus* M7W1 (*mtmW*⁺) mutant strain resulted in a 2-fold increase in the production of mithramycin SK and a 5-fold increase in the production of mithramycin SDK. Both of these derivatives have improved anticancer activity as compared to the parent compound mithramycin³⁶. Remarkably, this work demonstrated that pathway engineering can be used to increase production titers of valuable polyketide analogs with improved anticancer properties. Similar techniques could be utilized to enhance production titers of clinically important anthracycline analogs.

1.3. Harnessing β -oxidation for polyketide biosynthesis

Recent studies have identified new metabolic targets for overexpression to augment carbon flux towards polyketide biosynthesis, a critical development that could increase the yields of analogs that were previously unisolable. *Streptomyces coelicolor*, a model actinomycete for studying actinorhodin biosynthesis, stores much of its carbon as triacylglycerols following the logarithmic phase growth³⁷. Deep sequencing of the transcriptome of wildtype actinorhodin producer *S. coelicolor* M145 and an industrial actinorhodin overproducer, *S. coelicolor* HY01 revealed a significant increase of β -oxidation degradation products in the industrial producer strain. The transcripts corresponding to genes involved in β -oxidation were significantly upregulated during the stationary phase in *S. coelicolor* M145 and *S. coelicolor* HY01. Specifically, acyltransferase *sco6196* was significantly upregulated during the stationary phase in the HY01 strain as compared to the M145 wildtype, which provided a clue as to the enzyme which might be responsible for higher carbon flux towards actinorhodin. The identification of acyltransferase *sco6196* as a potential “metabolic switch” bridging β -oxidation to polyketide synthesis is potentially a universal strategy for enhancing production titers of anthracyclines in most actinomycetes (Figure 4)³⁷.

2. Advances in glycosylation of anthracyclines

Glycosylation is an indispensable biosynthetic modification that influences the antitumoral activity of the anthracyclines⁴. Glycosyltransferases (GTs) are enzymes that catalyze the attachment of deoxysugar moieties to anthracyclinone scaffolds, which recognize a deoxysugar donor substrate and an anthracyclinone acceptor substrate³⁸. An exhaustive description of deoxysugar biosynthesis is beyond the scope of this review, though several comprehensive reviews have previously been published on this subject^{39–41}. In this section, we describe novel advances in glycodiversification of anthracyclines due to deoxysugar pathway engineering and site-directed mutagenesis of glycosyltransferases. These findings set the stage for future combinatorial biosynthesis of rationally designed anthracyclines with substitutions in the glycosylation pattern.

2.1. Elloramycin

Compounds **5** and **6** are anthracycline antibiotics produced by *Streptomyces olivaceus* strain Tü 2353 (Figure 2)⁴². Recently, the mechanism of action for the tetracenomycins was shown to occur through inhibition of peptide translation via binding to the large ribosomal subunit of prokaryotes and humans, which accounts for their dual antibacterial and anticancer activities⁴³. **5** features an 8-*O*-glycosidically linked 2, 3, 4-tri-*O*-methyl- α -l-rhamnose sugar appendage. The biosynthetic gene cluster for production of **5** has been cloned on cosmid cos16F4 and encodes the genes necessary for the biosynthesis of polyketides **5** and **6**, in addition to the gene for the sugar-flexible glycosyltransferase, *elmGT*⁴⁴. The *Streptomyces lividans* (cos16F4) heterologous expression system is an ideal platform for assessing the combinatorial biosynthesis of TDP-deoxysugar pathways. ElmGT exhibits remarkable flexibility towards the transfer of many TDP-deoxysugar substrates to **6**, including > 20 different deoxysugars in both d- and l-configurations^{45–49}. Salas and coworkers generated a series of “sugar plasmids” directing biosynthesis of TDP-deoxysugar pathways using the multicopy plasmid pEM4 and expression of biosynthetic genes from the strong *ermE***p*

erythromycin resistance up-promoter⁵⁰. In one study, Nybo et al. generated a construct, pKOL, expressing the *oleSEVWL* genes from the TDP-l-oleandrose pathway for the formation of TDP-4-keto-l-olivose. Heterologous expression of plasmid pKOL in the *Streptomyces lividans* (cos16F4) host resulted in the successful generation of two derivatives, including the known analog, 8-demethyl-8- α -l-olivoyl-tetracenomycin C and the new analog 8-demethyl-8-(4'-keto)- α -l-olivoyl-tetracenomycin C⁵¹. This report revealed additional substrate flexibility by ElmGT towards a TDP-4-keto-l-sugar, which is unusual among natural product GTs.

2.2. Nogalamycin

The **3** biosynthetic gene cluster (*snog*) from *Streptomyces nogalater* ATCC 27451 has been cloned in *Streptomyces albus* J1074⁵². Heterologous expression of cosmid pSnogaori containing the majority of the gene cluster resulted in the production of nogalamycinone, nogalamycin R (**14**), nogalamycin F (**15**), and 3',4'-demethoxynogalose-1-hydroxynogalamycinone (**16**) (Figure 5). Expression of the entire metabolic pathway using a two-plasmid system led to formation of **3** and confirmed that all biosynthetic genes were present⁵².

The production of **15** by pSnogaori was surprising since an l-olivose sugar was featured at the 1-position instead of the expected l-nogalamine, which hinted at relaxed substrate flexibility on the part of glycosyltransferase SnogD. This result was explained due to the endogenous TDP-l-olivose biosynthesis in *S. albus* J1074, which effectively competed with TDP-l-rhodamine for binding by SnogD. The functions of the two glycosyltransferases SnogD and SnogE were studied with gene inactivation experiments. The strain lacking *snogD* produced primarily **16** and whereas, in the absence of *snogE*, *S. albus* produced primarily nogalamycinone, which established SnogE as the 7-*O*-L-nogalose glycosyltransferase and SnogD as the 1-*O*-L-rhodaminyl glycosyltransferase, respectively.

Structure determination of the glycosyltransferase SnogD from the nogalamycin biosynthetic pathway to 2.6 Å resolution to gain insight into the mechanism of carbohydrate transfer in anthracycline biosynthesis⁵³. The authors determined the structure of the *apo*-enzyme and the enzyme with a bound nucleotide, 2-deoxyuridine-5'-diphosphate. SnogD consists of one Rossmann fold in the *N*-terminal aglycone acceptor domain (residues 1–209) and one Rossmann fold in the *C*-terminal sugar donor domain (residues 228–390). This framework is characteristic of the glycosyltransferase B family (GT-B). The authors inactivated residues His25 and His301, which resulted in the abrogated function of the resulting SnogD mutants when expressed *in vitro* and *in vivo*. This is the first structural report of a crystallized anthracycline glycosyltransferase, which opens the door for future attempts at glycosyltransferase engineering to expand the substrate flexibility of these utilitarian enzymes towards accepting alternative aglycones and TDP-deoxysugar donors. Engineering of SnogD, for example, via the introduction of single or multiple point mutations or via rational domain swapping could afford new glycosyltransferase catalysts useful for deoxysugar interchange experiments (Figure 6).

The key structural feature of **3** is the attachment of l-nogalamine with an additional C5''-C2 bond, which positions the carbohydrate unit perpendicular to the aglycone that allows

interactions with the major groove of DNA⁵⁴. In addition, both C2'' and C4'' hydroxyl groups of l-nogalamine are important for hydrogen bonding interactions of **3** with DNA⁵⁴. Nonetheless, the pathway intermediates isolated from *S. albus* typically contained l-rhodosamine (2''-deoxy-4''-*epi*-l-nogalamine) as the carbohydrate unit. Recently, the Rieske enzyme SnoT and two non-heme Fe(II) and α -ketoglutarate dependent enzymes SnoK and SnoN are responsible for late-stage modifications in the biosynthesis of l-nogalamine^{55,56}. Complementation experiments with *snoN* in the **14**-producing strain resulted in new 4''-epimerized nogalamycins: 4''-*epi*-nogalamycin R (**17**) and 4''-*epi*-7-denogalosyl-7-*O*- α -l-oliviosyl-nogalamycin R (**18**) (Figure 5). The deletion of *snoK* from pSnogaORI resulted in the production of new nogalamycins lacking the C5''-2 carbocycle: 10-*O*- α -l-rhodosamine-nogalamycin F (**19**) and 10-*O*- α -l-rhodosamine-7-denogalosyl-7-*O*- α -l-oliviosyl-nogalamycin F (Figure 5) (**20**). The sequence of events leading to the formation of **3** includes 2''-hydroxylation of 1-*O*-l-rhodosamine by SnoT, followed by C5''-C2 carbocyclization by SnoK and 4'' epimerization by SnoN (Figure 7). Non-heme Fe(II) and α -ketoglutarate dependent enzymes can perform demanding oxidative transformations using a reactive Fe(IV)=O center. Despite the drastically different chemistry catalyzed by SnoK and SnoN, the catalytic difference appears to depend largely on the positioning of the substrates in front of the activated iron-oxo center. This was demonstrated in a recent study where SnoN was engineered to catalyze carbocyclization after insertion of just three residues from SnoK⁵⁷.

2.3. Keyicin

Compound **7** was discovered using an innovative co-culturing technique between *Rhodococcus sp.* WMMA185 and *Micromonospora sp.* WMMB235 that elicited the expression of the cryptic **7** biosynthetic gene cluster (*kyc*) from the latter host⁵⁸. The **7** biosynthetic pathway contains a non-heme iron enzyme ortholog, *kyc54*, of *snoK* from nogalamycin biosynthesis that putatively catalyzes the formation of the C2-C5'' bond in the epoxyoxocin ring system⁵⁵. The epoxyoxocin ring system of **7** is inverted at C4' relative to nogalamycin, which the authors hypothesized is due to the presence of the C4'-*O*-glycosidically linked trisaccharide containing 2-deoxy-l-fucose, a novel l-configured nitrosugar (e.g. 3''-demethoxy-l-evernitrose), and 2-deoxy-l-fucose (Figure 2). **7** also contains a tetrasaccharide appended at the 7-*O*-position composed of l-rhodosamine, 2-deoxy-l-fucose, a second novel nitrosugar (e.g. 3''-demethoxy-l-rubranitrose), and 2-deoxy-l-fucose (Figure 2). In total, there are seven putative GTs (e.g. *kyc12*, *kyc20*, *kyc24*, *kyc25*, *kyc29*, *kyc32*, and *kyc52*) responsible for the transfer of the seven deoxysugar moieties. Supporting evidence for participation of the encoded GT gene products in glycosylation of the **7** polyketide scaffold was provided by proteomics studies of 8 day-grown cultures of *Micromonospora sp.* WMMB235 in which four of the GT proteins were detected at the time of greatest production of glycosylated metabolites⁵⁹. These studies have opened the door for heterologous expression of these newly identified GT catalysts and deoxysugar biosynthetic enzymes in other anthracycline producing organisms, which could result in the production of anthracyclines decorated with novel nitrosugars.

2.4. Doxorubicin

1 and **2** are the best-characterized anthracyclines that are currently used in the clinic, and they have broad-spectrum activity against a variety of human cancers⁶⁰. Like the other anthracyclines, daunorubicin and doxorubicin inhibit the growth of cancer by poisoning the action of topoisomerase II on supercoiled DNA⁶¹. The polyketide functionality intercalates into the GC-rich DNA and the indispensable 7-*O*-l-daunosamine moiety anchors the drug inside the DNA double helix⁸. The carbohydrate moiety is an attractive functionality for the alteration of structure-activity-relationships (SAR) since this position influences the potency and efficacy of the anthracycline (Figure 1)⁸. In a pioneering study, *S. peucetius* was engineered for the production of 4'-*epi*-doxorubicin (e.g. epirubicin) via knockout of the endogenous TDP-4'-keto- 2,3,6-trideoxyhexulose reductase gene *dnmV* and expression of alternative 4-ketoreductase genes *eryBIV* and *avrE*⁶². Epirubicin is a clinically advantageous derivative of doxorubicin since it exhibits a two-fold higher maximum lifetime dose as compared to doxorubicin⁶³.

1 and **2** are produced by the actinomycete *Streptomyces peucetius*^{64,65}, yet the native production host exhibits several transcriptional and metabolic limitations that diminish production titers of **2** and the most biologically active analogs³². Therefore, several groups have developed heterologous expression hosts for the production of glycosylated analogs of daunorubicin. The heterologous host, *Streptomyces venezuelae*, has been developed for combinatorial biosynthetic expression of anthracycline glycosyltransferase and deoxysugar biosynthetic genes to produce glycosylated derivatives of doxorubicin⁶⁶. The strain was engineered to confer self-resistance to **2** by incorporation of the doxorubicin resistance genes *drrABC*. The genetic expression of "deoxysugar plasmids" in actinomycete hosts results in flooding the biosynthetic pathway with deoxysugar donors, which can outcompete endogenous deoxysugars for binding inside the active site of glycosyltransferases^{67,68}. The authors hypothesized that if the glycosyltransferase active site exhibits some flexibility towards alternative deoxysugar donors, then the foreign sugar can be appended to the anthracycline aglycone. The authors generated constructs encoding several heterologous TDP-deoxysugar biosynthetic pathways: TDP-l-daunosamine (**10**), TDP-l-rhodamine (**11**), TDP-3-*N*-methyl-l-daunosamine (**21**), TDP-4-*epi*-l-daunosamine (**22**), TDP-3-*N*-methyl-4-*epi*-l-daunosamine (**23**), TDP-l-nogalamine (**24**), TDP-l-ristosamine (**25**), TDP-3-*N*-methyl-l-ristosamine (**26**), TDP-l-megosamine (**27**), TDP-4-*epi*-l-vancosamine (**28**), TDP-l-rhamnose (**29**), TDP-d-olivose (**30**), TDP-l-olivose (**31**), TDP-d-digitoxose (**32**), and TDP-l-digitoxose (**33**) (Figure 8).

The authors conducted a biotransformation experiment in which they fed **9** into the strain co-expressing the resistance genes, glycosyltransferase, and heterologous deoxysugar pathways. In this work, the authors were able to reconstitute the late doxorubicin biosynthetic steps and produce $2.8 \pm 0.5 \mu\text{M}$ **12**, $0.9 \pm 0.04 \mu\text{M}$ **1**, and $1.1 \pm 0.13 \mu\text{M}$ **2**. The glycosyltransferase AknS and its CYP450-auxiliary protein AknT exhibited surprising donor substrate flexibility towards non-canonical TDP-deoxysugars. AknST demonstrated turnover of TDP-l-daunosamine, TDP-l-rhodamine, TDP-l-ristosamine, TDP-l-vancosamine, TDP-d-digitoxose, TDP-l-digitoxose, and TDP-l-rhamnose. In total, the authors generated twenty anthracyclines, including seven new rhodomycin D derivatives that were characterized by

HPLC-ESI-MS/MS analysis (**1**, **2**, **12**, **36** – **52**) (Figure 9). However, production titers of the new derivatives were too low to enable NMR spectroscopic characterization, which indicates further metabolic engineering efforts are required to harness the full potential of the method.

A one-pot combinatorial biosynthesis system was established in *Streptomyces venezuelae* for the production of aglycones and TDP-deoxysugars⁶⁹. The PKS genes (*dpsABGCDEFY* + *dnrGCDEF*) required for the production of **8** and **9** were integrated into the ϕ C31 *attB* site of the *S. venezuelae* chromosome. The authors were able to achieve production and export of 3.78 mg/L **8** production in strain YJ183/pAKV and 0.68 mg/L **9** production in strain YJ183/pRHO. Co-cultivation of these strains with strains engineered to express glycosyltransferases and TDP-deoxysugar biosynthetic pathways led to the production of glycosylated anthracyclines. The authors interrogated the donor substrate flexibility of AknST towards **10**, **11**, **21**, **22**, **25**, and novel deoxysugars TDP-l-vancosamine (**28**), TDP-4-amino-*N*-demethyl-d-amosamine (**34**), and TDP-d-desosamine (**35**) (Figure 8). The authors generated 16 glycosylated analogs of doxorubicin, including 7 new compounds characterized by HPLC-ESI-MS/MS (**56** – **62**), though yields were too low for NMR spectroscopic structure elucidation (Figure 9). This work demonstrates that the substrate-flexible AknST and combinatorial biosynthesis of heterologous TDP-deoxysugar biosynthetic pathways are powerful tools for glycodiversification of anthracyclines.

3. Conclusion

The past two decades have witnessed a revitalization of the anthracyclines with respect to glycodiversification and pathway engineering of these molecules. Most anthracyclines in clinical use, such as epirubicin, pirarubicin, and idarubicin, are semi-synthetic derivatives of natural products⁷⁰. However, it is important to note that the chemical space available for modification by pathway engineering or organic synthesis differs significantly⁷¹. Of particular interest is the ability of *Actinomycetes* to generate hundreds of diverse carbohydrates through dedicated biosynthetic pathways that have now been characterized for the most part⁷². Glycosylation has a significant impact on the biological activity of anthracyclines, and therefore, glycodiversification of naturally occurring anthracyclines would allow access to previous underexplored chemical space for biological testing⁷³.

The development of *Streptomyces venezuelae* as chassis for combinatorial biosynthesis of novel glycosylated analogs offers an excellent starting point⁶⁶. These studies revealed, for the first time, the moderate substrate promiscuity of glycosyltransferases AknS, SnogE, and StfG towards non-canonical TDP-deoxysugar donor substrates. The approach is enhanced by a novel one-pot co-culturing system for synthesis of aklavinone, ϵ -rhodomycinone, and TDP-amino-trideoxysugars separately to generate new analogs⁷⁴. The major drawback of the methodology is that the production titers for most of these compounds were <10 mg/L due to insufficient catalytic efficiency of the glycosyltransferases towards non-cognate substrates. In future efforts, these foundational discoveries can be improved via the incorporation of pathway engineering and glycosyltransferase engineering.

The crystallization of SnogD provided the first insight into the structure of an anthracycline glycosyltransferase. The identification of discrete *N*-terminal aglycone acceptor and *C*-

terminal deoxysugar donor typical of glycosyltransferases sets the stage for future efforts to engineer these enzymes to perform an expanded repertoire of transfer reactions. Other glycosyltransferases, such as ElmGT, feature unusually relaxed donor-substrate specificity. For example, wildtype ElmGT efficiently transferred TDP-4'-keto-l-olivose to 8-DMTC, which was surprising, given that ElmGT was not able to previously turnover TDP-4'-keto-l-rhamnose, which more closely resembles its natural substrate⁵¹. Using a different approach, site-directed mutagenesis of the loosely conserved $\alpha/\beta/\alpha$ motif of the nucleoside-diphosphate binding region of ElmGT was engineered to modulate the deoxysugar transfer to 8-DMTC. Altogether, these discoveries signify that engineering of glycosyltransferases could provide additional enzymatic catalysts for transferring exotic deoxysugar donor substrates.

The last twenty years have seen the synthesis of new anthracycline analogs and the development of a deeper understanding of the systems by which these analogs can be created. Once the remaining issues regarding the specificity of carbohydrate transfer can be solved, hundreds of the next generation of anthracycline analogs can be developed in a rapid manner using synthetic biology to expand the chemical space of this important class of pharmaceuticals.

Acknowledgements

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award number R15CA252830 (S.E.N.), the National Science Foundation under Grant No. ENG-2015951 (S.E.N.), the Academy of Finland Grant No. 285971 (M.M.-K.), the Novo Nordisk Foundation Grant Nos. 21684 and 57511 (M.M.K.), and the Jane and Aatos Erkko Foundation (M.M.-K.).

Biographies

Katelyn V. Brown will graduate from Ferris State University in May of 2022 with a Biotechnology B.S. degree. She has been working in the Nybo Lab at the Ferris State University College of Pharmacy developing novel analogs of anthracyclines via combinatorial biosynthesis for two years. She plans to get a Ph.D. in either Medicinal Chemistry or Pharmacology after completing her degree.

Benjamin Nji Wandji, M.Sc. obtained his International Master of Science in MPD in Protein Science and Biotechnology at the Faculty of Biochemistry and Molecular Medicine,

University of Oulu, Finland in 2015. He started his Doctoral Program in Molecular Life Science (DPMLS) at the University of Turku, Finland in 2016 with a focus on the biosynthesis and evolution of anthracyclines.

Mikko Metsä-Ketelä received his Ph. D. degree from the University of Turku, Finland, in 2003 on his work on the biosynthesis of aromatic polyketides. He continued to explore microbial natural products during his post-doctoral studies at the Leibniz Institute for Natural Product Research and Infection Biology (Prof. Christian Hertweck), Jena, Germany, and at the Karolinska Institute (Prof. Gunter Schneider), Stockholm, Sweden. He returned to Turku in 2009 to establish his own research group and was appointed Associate Professor in Biochemistry in 2017.

S. Eric Nybo received his Ph.D. degree from the University of Kentucky, College of Pharmacy in 2011 on his work concerning biosynthesis of anticancer polyketides. He pursued postdoctoral studies in terpene biosynthesis and metabolic engineering (Prof. Dr. Joseph Chappell) at the University of Kentucky, College of Pharmacy from 2011 to 2014. He was hired as a faculty member at Ferris State University, College of Pharmacy in 2014 where he started his independent research program working with undergraduate students on metabolic engineering of natural products and was promoted to Associate Professor in 2019.

References

- (1). Williams ST; Wellington EMH Actinomycetes; John Wiley & Sons, Ltd, 2015; pp 969–987. 10.2134/agronmonogr9.2.2ed.c45.
- (2). Nybo SE; Kharel MK Recent Developments in the Quest for Novel Microbial Natural Products In Studies in Natural Products Chemistry; Elsevier B.V., 2018; Vol. 59, pp 109–152. 10.1016/B978-0-444-64179-3.00004-9.
- (3). Lown JW Discovery and Development of Anthracycline Antitumour Antibiotics. Chemical Society Reviews 1993, 22 (3), 165–176. 10.1039/CS9932200165.
- (4). Minotti G; Menna P; Salvatorelli E; Cairo G; Gianni L Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacological Reviews 2004, 56 (2), 185–229. 10.1124/pr.56.2.6. [PubMed: 15169927]
- (5). Menna P; Minotti G; Salvatorelli E In Vitro Modeling of the Structure–Activity Determinants of Anthracycline Cardiotoxicity. Cell Biology and Toxicology 2007, 23 (1), 49–62. 10.1007/s10565-006-0143-8. [PubMed: 17031515]

- (6). Zeman SM; Phillips DR; Crothers DM Characterization of Covalent Adriamycin-DNA Adducts. *Proceedings of the National Academy of Sciences of the United States of America* 1998, 95 (20), 11561–11565. 10.1073/pnas.95.20.11561. [PubMed: 9751705]
- (7). di Marco A; Casazza AM; Dasdia T; Necco A; Pratesi G; Rivolta P; Velcich A; Zaccara A; Zunino F Changes of Activity of Daunorubicin, Adriamycin and Stereoisomers Following the Introduction or Removal of Hydroxyl Groups in the Amino Sugar Moiety. *Chemico-Biological Interactions* 1977, 19 (3), 291–302. 10.1016/0009-2797(77)90052-7. [PubMed: 597963]
- (8). Zunino F; Pratesi G; Perego P Role of the Sugar Moiety in the Pharmacological Activity of Anthracyclines: Development of a Novel Series of Disaccharide Analogs. *Biochemical Pharmacology* 2001, 61 (8), 933–938. 10.1016/S0006-2952(01)00522-6. [PubMed: 11286984]
- (9). Battisti RF; Zhong Y; Fang L; Gibbs S; Shen J; Nadas J; Zhang G; Sun D; Modifying the Sugar Moieties of Daunorubicin Overcomes P-Gp-Mediated Multidrug Resistance. *Molecular Pharmaceutics* 2007, 4 (1), 140–153. 10.1021/mp060075v. [PubMed: 17274671]
- (10). Zhang S; Liu X; Bawa-Khalfe T; Lu LS; Lyu YL; Liu LF; Yeh ETH Identification of the Molecular Basis of Doxorubicin-Induced Cardiotoxicity. *Nature Medicine* 2012, 18 (11), 1639–1642. 10.1038/nm.2919.
- (11). Qiao X; van der Zanden SY; Wander DPA; Borràs DM; Song JY; Li X; van Duikeren S; van Gils N; Rutten A; van Herwaarden T; van Tellingen O; Giacomelli E; Bellin M; Orlova V; Tertoolen LGJ; Gerhardt S; Akkermans JJ; Bakker JM; Zuur CL; Pang B; Smits AM; Mummery CL; Smit L; Arens R; Li J; Overkleeft HS; Neefjes J Uncoupling DNA Damage from Chromatin Damage to Detoxify Doxorubicin. *Proceedings of the National Academy of Sciences of the United States of America* 2020, 117 (26), 15182–15192. 10.1073/pnas.1922072117. [PubMed: 32554494]
- (12). BROCKMANN H [Anthracyclinones and Anthracyclines. (Rhodomycinone, Pyrromycinone and Their Glycosides)]. <http://www.ncbi.nlm.nih.gov/pubmed/14287135> (accessed Jul 26, 2020).
- (13). Kawai H; Hayakawa Y; Nakagawa M; Furihata K; Seto H; Otake N Arugomycin, A New Anthracycline Antibiotic Ii. Structural Elucidation. *The Journal of Antibiotics* 1987, 40 (9), 1273–1282. 10.7164/antibiotics.40.1273. [PubMed: 3479413]
- (14). Laatsch H; Fotso S Anthracycline Chemistry and Biology I; Krohn K, Ed.; Topics in Current Chemistry; Springer Berlin Heidelberg: Berlin, Heidelberg, 2008; Vol. 282 10.1007/978-3-540-75815-0.
- (15). Kantola J; Kunnari T; Hautala A; Hakala J; Ylihönko K; Mäntsälä P Elucidation of Anthracyclinone Biosynthesis by Stepwise Cloning of Genes for Anthracyclines from Three Different *Streptomyces* Spp. *Microbiology (Reading, England)* 2000, 146 (Pt 1 (1), 155–163. 10.1099/00221287-146-1-155.
- (16). Castaldo G; Zucko J; Heidelberger S; Vujaklija D; Hranueli D; Cullum J; Wattana-Amorn P; Crump MP; Crosby J; Long PF Proposed Arrangement of Proteins Forming a Bacterial Type II Polyketide Synthase. *Chemistry & Biology* 2008, 15 (11), 1156–1165. 10.1016/J.CHEMBIOL.2008.09.010. [PubMed: 19022176]
- (17). Grimm A; Madduri K; Ali A; Hutchinson CR Characterization of the *Streptomyces Peucetius* ATCC 29050 Genes Encoding Doxorubicin Polyketide Synthase. *Gene* 1994, 151 (1–2), 1–10. 10.1016/0378-1119(94)90625-4. [PubMed: 7828855]
- (18). ECKARDT K; TRESSELT D; SCHUMANN G; IHN W; WAGNER C Isolation and Chemical Structure of Aklanonic Acid, an Early Intermediate in the Biosynthesis of Anthracyclines. *The Journal of Antibiotics* 1985, 38 (8), 1034–1039. 10.7164/antibiotics.38.1034. [PubMed: 3862658]
- (19). Connors NC; Bartel PL; Strohl WR Biosynthesis of Anthracyclines: Enzymic Conversion of Aklanonic Acid to Aklavinone and -Rhodomycinone by Anthracycline-Producing *Streptomyces*. *Journal of General Microbiology* 1990, 136 (9), 1887–1894. 10.1099/00221287-136-9-1887.
- (20). Filippini S; Solinas MM; Breme U; Schluter MB; Gabellini D; Biamonti G; Colombo AL; Garofano L *Streptomyces Peucetius* Daunorubicin Biosynthesis Gene, DnrF: Sequence and Heterologous Expression. *Microbiology* 1995, 141 (4), 1007–1016. 10.1099/13500872-141-4-1007. [PubMed: 7773378]
- (21). Singh B; Lee CB; Sohng JK Precursor for Biosynthesis of Sugar Moiety of Doxorubicin Depends on Rhamnose Biosynthetic Pathway in *Streptomyces Peucetius* ATCC 27952. *Applied*

Microbiology and Biotechnology 2010, 85 (5), 1565–1574. 10.1007/s00253-009-2225-z. [PubMed: 19777229]

- (22). Otten SL; Gallo MA; Madduri K; Liu X; Hutchinson CR Cloning and Characterization of the Streptomyces Peucetius DnmZUV Genes Encoding Three Enzymes Required for Biosynthesis of the Daunorubicin Precursor Thymidine Diphospho-L-Daunosamine. Journal of Bacteriology 1997, 179 (13), 4446–4450. [PubMed: 9209071]
- (23). Olano C; Lomovskaya N; Fonstein L; Roll JT; Hutchinson CR A Two-Plasmid System for the Glycosylation of Polyketide Antibiotics: Bioconversion of ε-Rhodomyacinone to Rhodomyacin D. Chemistry and Biology 1999, 6 (12), 845–855. 10.1016/S1074-5521(00)80004-6. [PubMed: 10631513]
- (24). Madduri K; Hutchinson CR Functional Characterization and Transcriptional Analysis of the DnrR1 Locus, Which Controls Daunorubicin Biosynthesis in Streptomyces Peucetius. Journal of Bacteriology 1995, 177 (5), 1208–1215. [PubMed: 7868593]
- (25). Gallo MA; Ward J; Hutchinson CR The DnrM Gene in Streptomyces Peucetius Contains a Naturally Occurring Frameshift Mutation That Is Suppressed by Another Locus Outside of the Daunorubicin-Production Gene Cluster. Microbiology 1996, 142 (2), 269–275. 10.1099/13500872-142-2-269. [PubMed: 8932700]
- (26). Otten SL; Liu X; Ferguson J; Hutchinson CR; Hutchinson ACR Cloning and Characterization of the Streptomyces Peucetius DnrQS Genes Encoding a Daunosamine Biosynthesis Enzyme and a Glycosyl Transferase Involved in Daunorubicin Biosynthesis. Journal of Bacteriology 1995, 177 (22), 6688–6692. [PubMed: 7592454]
- (27). Lu W; Leimkuhler C; Gatto GJ; Kruger RG; Oberthür M; Kahne D; Walsh CT AknT Is an Activating Protein for the Glycosyltransferase AknS in L-Aminodeoxysugar Transfer to the Aglycone of Aclacinomycin A. Chemistry and Biology 2005, 12 (5), 527–534. 10.1016/j.chembiol.2005.02.016. [PubMed: 15911373]
- (28). Moncrieffe MC; Fernandez MJ; Spiteller D; Matsumura H; Gay NJ; Luisi BF; Leadlay PF Structure of the Glycosyltransferase EryCIII in Complex with Its Activating P450 Homologue EryCII. Journal of Molecular Biology 2012, 415 (1), 92–101. 10.1016/j.jmb.2011.10.036. [PubMed: 22056329]
- (29). Borisova SA; Liu H-WW Characterization of Glycosyltransferase DesVII and Its Auxiliary Partner Protein DesVIII in the Methymycin/Pikromycin Biosynthetic Pathway. Biochemistry 2010, 49 (37), 8071–8084. 10.1021/bi1007657. [PubMed: 20695498]
- (30). Dickens ML; Priestley ND; Strohl WR In Vivo and in Vitro Bioconversion of Epsilon-Rhodomyacinone Glycoside to Doxorubicin: Functions of DauP, DauK, and DoxA. Journal of bacteriology 1997, 179 (8), 2641–2650. 10.1128/JB.179.8.2641-2650.1997. [PubMed: 9098063]
- (31). Walczak RJ; Hines J; Strohl WR; Priestley ND; Bioconversion of the Anthracycline Analogue Desacetyladiamycin by Recombinant DoxA, a P450-Monooxygenase from Streptomyces Sp. Strain C5. 2001.
- (32). Malla S; Prasad Niraula N; Singh B; Liou K; Kyung Sohng J Limitations in Doxorubicin Production from Streptomyces Peucetius. Microbiological Research. 2010, pp 427–435. 10.1016/j.micres.2009.11.006. [PubMed: 20116225]
- (33). Malla S; Niraula NP; Liou K; Sohng JK Enhancement of Doxorubicin Production by Expression of Structural Sugar Biosynthesis and Glycosyltransferase Genes in Streptomyces Peucetius. Journal of Bioscience and Bioengineering 2009, 108 (2), 92–98. 10.1016/j.jbiosc.2009.03.002. [PubMed: 19619853]
- (34). Zabala D; Braña AF; Salas JA; Méndez C Increasing Antibiotic Production Yields by Favoring the Biosynthesis of Precursor Metabolites Glucose-1-Phosphate and/or Malonyl-CoA in Streptomyces Producer Strains. The Journal of Antibiotics 2016, 69 (3), 179–182. 10.1038/ja.2015.104. [PubMed: 26464013]
- (35). Zabala D; Braña AF; Flórez AB; Salas JA; Méndez C Engineering Precursor Metabolite Pools for Increasing Production of Antitumor Mithramycins in Streptomyces Argillaceus. Metabolic Engineering 2013, 20, 187–197. 10.1016/j.ymben.2013.10.002. [PubMed: 24148183]
- (36). Remsing LL; González AM; Nur-E-Alam M; José Fernández-Lozano M; Braña AF; Rix U; Oliveira MA; Méndez C; Salas JA; Rohr J Mithramycin SK, A Novel Antitumor Drug with Improved Therapeutic Index, Mithramycin SA, and Demycarosyl-Mithramycin SK: Three New

Products Generated in the Mithramycin Producer *Streptomyces Argillaceus* through Combinatorial Biosynthesis HHS Public Access. *J Am Chem Soc* 2003, 125, 5745–5753. 10.1021/ja034162h. [PubMed: 12733914]

- (37). Wang W; Li S; Li Z; Zhang J; Fan K; Tan G; Ai G; Lam SM; Shui G; Yang Z; Lu H; Jin P; Li Y; Chen X; Xia X; Liu X; Dannelly HK; Yang C; Yang Y; Zhang S; Alterovitz G; Xiang W; Zhang L Harnessing the Intracellular Triacylglycerols for Titer Improvement of Polyketides in *Streptomyces*. *Nature Biotechnology* 2020, 38 (1), 76–83. 10.1038/s41587-019-0335-4.
- (38). Liang D-M; Liu J-H; Wu H; Wang B-B; Zhu H-J; Qiao J-J Glycosyltransferases: Mechanisms and Applications in Natural Product Development. *Chemical Society Reviews* 2015, 44 (22), 8350–8374. 10.1039/C5CS00600G. [PubMed: 26330279]
- (39). Elshahawi SI; Shaaban KA; Kharel MK; Thorson JS A Comprehensive Review of Glycosylated Bacterial Natural Products. *Chemical Society Reviews* 2015, 44 (21), 7591–7697. 10.1039/c4cs00426d. [PubMed: 25735878]
- (40). White-Phillip J; Thibodeaux CJ; Liu H Enzymatic Synthesis of TDP-Deoxysugars. *Methods in enzymology* 2009, 459, 521–544. 10.1016/S0076-6879(09)04621-7. [PubMed: 19362653]
- (41). Thibodeaux CJ; Melancon CE; Liu HW Natural-Product Sugar Biosynthesis and Enzymatic Glycodiversification. *Angewandte Chemie - International Edition*. 2008, pp 9814–9859. 10.1002/anie.200801204. [PubMed: 19058170]
- (42). Zeeck A; Reuschenbach P; ZÄhner H; Rohr J Metabolic Products of Microorganisms. 2251) Elloramycin, a New Anthracycline-like Antibiotic from *Streptomyces Olivaceus* Isolation, Characterization, Structure and Biological Properties. *the Journal of Antibiotics* 1985, 38 (10), 1291–1301. 10.7164/antibiotics.38.1291. [PubMed: 3840789]
- (43). Osterman IA; Wieland M; Maviza TP; Lashkevich KA; Lukianov DA; Komarova ES; Zakalyukina Y. v.; Buschauer R; Shiriaev DI; Leyn SA; Zlamal JE; Biryukov M. v.; Skvortsov DA; Tashlitsky VN; Polshakov VI; Cheng J; Polikanov YS; Bogdanov AA; Osterman AL; Dmitriev SE; Beckmann R; Dontsova OA; Wilson DN; Sergiev P. v. Tetracenomycin X Inhibits Translation by Binding within the Ribosomal Exit Tunnel. *Nature Chemical Biology* 2020, 1–7. 10.1038/s41589-020-0578-x.
- (44). Decker H; Rohr J; Motamedi H; ZÄhner H; Hutchinson CRR Identification of *Streptomyces Olivaceus* Tü 2353 Genes Involved in the Production of the Polyketide Elloramycin; Elsevier, 1995; Vol. 166 10.1016/0378-1119(95)00573-7.
- (45). Pérez M; Lombó F; Zhu L; Gibson M; Braña AF; Rohr J; Salas JA; Méndez C Combining Sugar Biosynthesis Genes for the Generation of <sc>l</sc>- and <sc>d</sc>-Amicetose and Formation of Two Novel Antitumor Tetracenomycins. *Chem. Commun* 2005, 0 (12), 1604–1606. 10.1039/B417815G.
- (46). Lombó F; Gibson M; Greenwell L; Braña AF; Rohr J; Salas JA; Méndez C Engineering Biosynthetic Pathways for Deoxysugars: Branched-Chain Sugar Pathways and Derivatives from the Antitumor Tetracenomycin. *Chemistry & biology* 2004, 11 (12), 1709–1718. 10.1016/j.chembiol.2004.10.007. [PubMed: 15610855]
- (47). Rodríguez L; Oelkers C; Aguirrezabalaga I; Braña AF; Rohr JJ; Méndez C; Salas JA; Brana A F.; Rohr JJ; Mendez C; Salas JA Generation of Hybrid Elloramycin Analogs by Combinatorial Biosynthesis Using Genes from Anthracycline-Type and Macrolide Biosynthetic Pathways. *Journal of molecular microbiology and biotechnology* 2000, 2 (3), 271–276. [PubMed: 10937435]
- (48). Pérez M; Lombó F; Baig I; Braña AF; Rohr J; Salas JA; Méndez C Combinatorial Biosynthesis of Antitumor Deoxysugar Pathways in *Streptomyces Griseus*: Reconstitution of “Unnatural Natural Gene Clusters” for the Biosynthesis of Four 2,6-D-Dideoxyhexoses. *Applied and Environmental Microbiology* 2006, 72 (10), 6644–6652. 10.1128/AEM.01266-06. [PubMed: 17021216]
- (49). Fischer C; Rodríguez L; Patallo EP; Lipata F; Braña AF; Méndez C; Salas JA; Rohr J Digitoxosyltetracenomycin C and Glucosyltetracenomycin C, Two Novel Elloramycin Analogues Obtained by Exploring the Sugar Donor Substrate Specificity of Glycosyltransferase ElmGT. *Journal of natural products* 2002, 65 (11), 1685–1689. 10.1021/np020112z. [PubMed: 12444703]

- (50). Rodríguez L; Aguirrezabalaga I; Allende N; Braña AF; Méndez C; Salas JA Engineering Deoxysugar Biosynthetic Pathways from Antibiotic-Producing Microorganisms. *Chemistry & Biology* 2002, 9 (6), 721–729. 10.1016/s1074-5521(02)00154-0. [PubMed: 12079784]
- (51). Eric Nybo S; Shabaan KA; Kharel MK; Sutardjo H; Salas JA; Méndez C; Rohr J Ketooliviosyl-Tetracenomycin C: A New Ketosugar Bearing Tetracenomycin Reveals New Insight into the Substrate Flexibility of Glycosyltransferase ElmGT. *Bioorganic and Medicinal Chemistry Letters* 2012, 22 (6), 2247–2250. 10.1016/j.bmcl.2012.01.094. [PubMed: 22361136]
- (52). Siitonen V; Claesson M; Patrikainen P; Aromaa M; Mäntsälä P; Schneider G; Metsä-Ketelä M Identification of Late-Stage Glycosylation Steps in the Biosynthetic Pathway of the Anthracycline Nogalamycin. *ChemBioChem* 2012, 13 (1), 120–128. 10.1002/cbic.201100637. [PubMed: 22120896]
- (53). Claesson M; Siitonen V; Dobritsch D; Metsä-Ketelä M; Schneider G Crystal Structure of the Glycosyltransferase SnogD from the Biosynthetic Pathway of Nogalamycin in *Streptomyces Nogalater*. *FEBS Journal* 2012, 279 (17), 3251–3263. 10.1111/j.1742-4658.2012.08711.x. [PubMed: 22804797]
- (54). Smith CK; Davies GJ; Dodson EJ; Moore MH DNA—Nogalamycin Interactions: The Crystal Structure of d(TGATCA) Complexed with Nogalamycin. *Biochemistry* 1995, 34 (2), 415–425. 10.1021/bi00002a005. [PubMed: 7819233]
- (55). Siitonen V; Selvaraj B; Niiranen L; Lindqvist Y; Schneider G; Metsä-Ketelä M Divergent Non-Heme Iron Enzymes in the Nogalamycin Biosynthetic Pathway. *Proceedings of the National Academy of Sciences* 2016, 113 (19), 201525034 10.1073/pnas.1525034113.
- (56). Nji Wandji B; Siitonen V; Palmu K; Metsä-Ketelä M The Rieske Oxygenase SnoT Catalyzes 2''-Hydroxylation of 1-Rhodosamine in Nogalamycin Biosynthesis. *ChemBioChem* 2020, cbic.202000229. 10.1002/cbic.202000229.
- (57). Nji Wandji B; Siitonen V; Dinis P; Vukic V; Salminen TA; Metsä-Ketelä M Evolution-guided Engineering of Non-heme Iron Enzymes Involved in Nogalamycin Biosynthesis. *The FEBS Journal* 2020, 287 (14), 2998–3011. 10.1111/febs.15192.
- (58). Adnani N; Chevrette MG; Adibhatla SN; Zhang F; Yu Q; Braun DR; Nelson J; Simpkins SW; McDonald BR; Myers CL; Piotrowski JS; Thompson CJ; Currie CR; Li L; Rajski SR; Bugni TS Coculture of Marine Invertebrate-Associated Bacteria and Interdisciplinary Technologies Enable Biosynthesis and Discovery of a New Antibiotic, Keyicin. *ACS Chemical Biology* 2017, acschembio.7b00688. 10.1021/acschembio.7b00688.
- (59). Acharya D; Miller I; Cui Y; Braun DR; Berres ME; Styles MJ; Li L; Kwan J; Rajski SR; Blackwell HE; Bugni TS Omics Technologies to Understand Activation of a Biosynthetic Gene Cluster in *Micromonospora* Sp. WMMB235: Deciphering Keyicin Biosynthesis. *ACS Chemical Biology* 2019, 14 (6), 1260–1270. 10.1021/acschembio.9b00223. [PubMed: 31120241]
- (60). Weiss RB The Anthracyclines: Will We Ever Find a Better Doxorubicin? *Seminars in oncology* 1992, 19 (6), 670–686. 10.5555/uri:pii:009377549290036Z. [PubMed: 1462166]
- (61). Tewey KM; Rowe TC; Yang L; Halligan BD; Liu LF Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II. *Science (New York, N.Y.)* 1984, 226 (4673), 466–468. 10.1126/science.6093249.
- (62). Madduri K; Kennedy J; Rivola G; Inventi-Solari A; Filippini S; Zanuso G; Colombo AL; Gewain KM; Occi JL; MacNeil DJ; Hutchinson CR Production of the Antitumor Drug Epirubicin (4'-Epidoxorubicin) and Its Precursor by a Genetically Engineered Strain of *Streptomyces Peucetius*. *Nature biotechnology* 1998, 16 (1), 69–74. 10.1038/nbt0198-69.
- (63). Fumoleau P; Roché H; Kerbrat P; Bonnetterre J; Romestaing P; Fargeot P; Namer M; Monnier A; Montcuquet P; Goudier M-J; Luporsi E; French Adjuvant Study Group. Long-Term Cardiac Toxicity after Adjuvant Epirubicin-Based Chemotherapy in Early Breast Cancer: French Adjuvant Study Group Results. *Annals of Oncology* 2006, 17 (1), 85–92. 10.1093/annonc/mdj034. [PubMed: 16251204]
- (64). Arcamone F; Franceschi G; Penco S; Selva a. Adriamycin (14-Hydroxydaunomycin), a Novel Antitumor Antibiotic. *Tetrahedron letters* 1969, 40 (13), 1007–1010. 10.1016/S0040-4039(01)97723-8.

- (65). Arcamone F; Franceschi G; Orezzi P; Cassinelli G; Barbieri Wanda.; Mondelli Rosanna. Daunomycin I The Structure of Daunomycinone. *Journal of the American Chemical Society* 1964, 86 (23), 5334–5335. 10.1021/ja01077a059.
- (66). Han AR; Park JW; Lee MK; Ban YH; Yoo YJ; Kim EJ; Kim E; Kim BG; Sohng JK; Yoon YJ Development of a Streptomyces Venezuelae-Based Combinatorial Biosynthetic System for the Production of Glycosylated Derivatives of Doxorubicin and Its Biosynthetic Intermediates. *Applied and Environmental Microbiology* 2011, 77 (14), 4912–4923. 10.1128/AEM.02527-10. [PubMed: 21602397]
- (67). Pérez M; Baig I; Braña AF; Salas JA; Rohr J; Méndez C Generation of New Derivatives of the Antitumor Antibiotic Mithramycin by Altering the Glycosylation Pattern through Combinatorial Biosynthesis. *Chembiochem: a European journal of chemical biology* 2008, 9 (14), 2295–2304. 10.1002/cbic.200800299. [PubMed: 18756551]
- (68). Núñez LE; Nybo SE; González-Sabín J; Pérez M; Menéndez N; Braña AF; Shaaban KA; He M; Morís F; Salas JA; Rohr J; Méndez C A Novel Mithramycin Analogue with High Antitumor Activity and Less Toxicity Generated by Combinatorial Biosynthesis. *Journal of medicinal chemistry* 2012, 55 (12), 5813–5825. 10.1021/jm300234t. [PubMed: 22578073]
- (69). Kim E; Moore BS; Yoon YJ Reinvigorating Natural Product Combinatorial Biosynthesis with Synthetic Biology. *Nature chemical biology* 2015, 11 (9), 649–659. 10.1038/nchembio.1893. [PubMed: 26284672]
- (70). Arcamone F; Animati F; Capranico G; Lombardi P; Pratesi G; Manzini S; Supino R; Zunino F New Developments in Antitumor Anthracyclines Pharmacology and Therapeutics. Elsevier Inc. 10 1, 1997, pp 117–124. 10.1016/S0163-7258(97)00096-X.
- (71). Niemi J; Metsä-Ketelä M; Schneider G; Mäntsälä P Biosynthetic Anthracycline Variants. *Topics in Current Chemistry*. 2008, pp 75–99. 10.1007/128-2007-13.
- (72). Thibodeaux CJ; Melancon CE; Liu H Unusual Sugar Biosynthesis and Natural Product Glycodiversification. *Nature* 2007, 446 (7139), 1008–1016. [PubMed: 17460661]
- (73). Temperini C; Cirilli M; Aschi M; Ughetto G Role of the Amino Sugar in the DNA Binding of Disaccharide Anthracyclines: Crystal Structure of the Complex MAR70/d(CGATCG). *Bioorganic and Medicinal Chemistry* 2005, 13 (5), 1673–1679. 10.1016/j.bmc.2004.12.007. [PubMed: 15698785]
- (74). Kim E; Song MC; Kim MS; Beom JY; Jung JA; Cho HS; Yoon YJ One-Pot Combinatorial Biosynthesis of Glycosylated Anthracyclines by Cocultivation of Streptomyces Strains Producing Aglycones and Nucleotide Deoxysugars. *ACS Combinatorial Science* 2017, 19 (4), 262–270. 10.1021/acscmbosci.6b00194. [PubMed: 28191923]

Figure 1.
The binding of anthracyclines to DNA. A) Structure of the nogalamycin-DNA complex (PDB: 182D) reveals the intercalation of the anthraquinone aglycone between DNA bases and positioning of the carbohydrate unit at 7-position in the minor groove of DNA, B) Formation of methylene adducts of doxorubicin to double-stranded DNA.

Figure 2.

Structures of anthracycline natural products. Sugar moieties are indicated in red.

Figure 3.

Scheme for polyketide biosynthesis of daunorubicin (**1**) and doxorubicin (**2**) (panel A) and deoxysugar biosynthesis of TDP-L-daunosamine (**10**) and TDP-L-rhodosamine (**11**) (panel B).

Figure 4. Biochemical scheme for anthracycline pathway engineering. Enzymes that have been overexpressed are indicated by green arrows. Pgm = phosphoglucomutase, GS = NDP-d-glucose synthase, 4,6-DH = NDP-d-glucose-4,6-dehydratase, GT = glycosyltransferase, ACS = acyltransferase, *sco6196* = acyltransferase from *Streptomyces coelicolor* M145, ACCase = acetyl-CoA carboxylase complex, TAG = triacylglycerols, TDP = thymidine diphosphate.

Figure 5.
Glycosylated analogs of nogalamycin reported from gene inactivation experiments.

Figure 6. Structural biology and site-directed mutagenesis of SnogD as strategies for developing new glycosyltransferase catalysts. Mutations can focus on single or multiple points mutations or even swapping entire regions or domains between glycosyltransferases.

Figure 7.

Late-stage biosynthesis of nogalamycin via SnoT, SnoK, and SnoN. SnoT is a Rieske oxygenase that carries out 2''-hydroxylation of 1-*O*-l-rhodosamine. SnoK and SnoN are non-heme iron enzymes that form the C5''-C2 carbon-carbon bond and catalyze 4''-epimerization of **3**, respectively.

Figure 8.
TDP-deoxysugar donors used for glycodiversification of anthracyclines.

Number	Compound	R ₁	R ₂	R ₃	R ₄	R ₅
12	Rhomycin D	H	OH	CO ₂ CH ₃	CH ₂ CH ₃	I
36	3'-N-methyl-rhomycin D	H	OH	CO ₂ CH ₃	CH ₂ CH ₃	II
37	L-rhodosaminy-rhomycin D	H	OH	CO ₂ CH ₃	CH ₂ CH ₃	III
38	4'-epi-rhomycin D	H	OH	CO ₂ CH ₃	CH ₂ CH ₃	IV
39	3'-N-methyl-4'-epi-rhomycin D	H	OH	CO ₂ CH ₃	CH ₂ CH ₃	V
40	L-ristosaminy-rhomycin D	H	OH	CO ₂ CH ₃	CH ₂ CH ₃	VI
41	3'-N-methyl-L-ristosaminy-rhomycin D	H	OH	CO ₂ CH ₃	CH ₂ CH ₃	VII
42	4'-epi-L-vancosaminy-rhomycin D	H	OH	CO ₂ CH ₃	CH ₂ CH ₃	VIII
43	L-rhamnosyl-rhomycin D	H	OH	CO ₂ CH ₃	CH ₂ CH ₃	IX
44	D-olivosyl-rhomycin D	H	OH	CO ₂ CH ₃	CH ₂ CH ₃	X
45	L-olivosyl-rhomycin D	H	OH	CO ₂ CH ₃	CH ₂ CH ₃	XI
46	D-digitoxosyl-rhomycin D	H	OH	CO ₂ CH ₃	CH ₂ CH ₃	XII
47	L-digitoxosyl-rhomycin D	H	OH	CO ₂ CH ₃	CH ₂ CH ₃	XIII
1	Daunorubicin	CH ₃	OH	H	COCH ₃	I
48	3'-N-methyl-daunorubicin	CH ₃	OH	H	COCH ₃	II
49	4'-epi-daunorubicin	CH ₃	OH	H	COCH ₃	IV
50	4'-epi-L-vancosaminy-daunorubicin	CH ₃	OH	H	COCH ₃	VIII
2	Doxorubicin	CH ₃	OH	H	COCH ₂ OH	I
51	3'-N-methyl-doxorubicin	CH ₃	OH	H	COCH ₂ OH	II
52	Epirubicin	CH ₃	OH	H	COCH ₂ OH	IV
53	L-daunosaminy-aklavinone	H	H	CO ₂ CH ₃	CH ₂ CH ₃	I
54	3'-N-methyl-L-daunosaminy-aklavinone	H	H	CO ₂ CH ₃	CH ₂ CH ₃	II
55	L-rhodosaminy-aklavinone	H	H	CO ₂ CH ₃	CH ₂ CH ₃	III
56	4'-epi-L-daunosaminy-aklavinone	H	H	CO ₂ CH ₃	CH ₂ CH ₃	IV
57	L-ristosaminy-aklavinone	H	H	CO ₂ CH ₃	CH ₂ CH ₃	VI
58	4'-epi-L-vancosaminy-aklavinone	H	H	CO ₂ CH ₃	CH ₂ CH ₃	VIII
59	4'-N-demethyl-D-amosaminy-aklavinone	H	H	CO ₂ CH ₃	CH ₂ CH ₃	XIV
60	4'-N-demethyl-D-amosaminy-rhomycin D	H	OH	CO ₂ CH ₃	CH ₂ CH ₃	XIV
61	D-desosaminy-aklavinone	H	H	CO ₂ CH ₃	CH ₂ CH ₃	XV
62	D-desosaminy-rhomycin D	H	OH	CO ₂ CH ₃	CH ₂ CH ₃	XV

Figure 9.

Glycodiversified anthracycline analogs produced via combinatorial biosynthesis. New analogs produced in studies by Han et al.⁶⁶ and Ryu et al.⁷⁴ are indicated in red typeface.